Michael J. Levitt
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Core Scientific falls 3% as TeraWulf expands power contracts. Core Scientific shares dropped 3% in recent trading, moving in tandem with broader weakness in the digital infrastructure sector. This decline occurred alongside TeraWulf's 5% slide, which followed the announcement that the company doubled its Muskie power contract to 1 gigawatt. The movement reflects ongoing volatility in the data center and mining space, where significant infrastructure expansions are currently being priced in by the market.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Kayne Anderson BDC Sets Q3 2026 Earnings Date. Kayne Anderson BDC has announced the schedule for its third-quarter 2026 earnings release and conference call. This upcoming event will provide investors with updated financial results and management commentary. The stock currently carries a high dividend yield, which often draws attention ahead of quarterly reports.
Transaction History
| HLF | ▲ Buy | Grant | 11,879 | $0 | 5/8/2026 | View on chart |
| HLF | ▲ Buy | Grant | 21,857 | $0 | 5/2/2025 | View on chart |
| HLF | ▲ Buy | Grant | 15,657 | $0 | 5/3/2024 | View on chart |
| CORZ | ▼ Sell | Other | 869,110 | — | 1/23/2024 | View on chart |
| CORZ | ▼ Sell | Other | 3,835,368 | — | 1/23/2024 | View on chart |
| CORZ | ▼ Sell | Other | 10,629,668 | — | 1/23/2024 | View on chart |
| CORZ | ▼ Sell | Other | 800,210 | — | 1/23/2024 | View on chart |
| CORZ | ▼ Sell | Other | 20,094,478 | — | 1/23/2024 | View on chart |
| CORZ | ▼ Sell | Other | 41,470 | — | 1/23/2024 | View on chart |
| CORZ | ▼ Sell | Other | 869,110 | — | 1/23/2024 | View on chart |
| CORZ | ▼ Sell | Other | 3,199,414 | — | 1/23/2024 | View on chart |
| CORZ | ▲ Buy | Grant | 20,094,478 | — | 1/23/2024 | View on chart |
| CORZ | ▲ Buy | Grant | 85,355 | — | 1/23/2024 | View on chart |
| CORZ | ▲ Buy | Grant | 41,470 | — | 1/23/2024 | View on chart |
| CORZ | ▲ Buy | Grant | 30,555 | — | 1/23/2024 | View on chart |
| CORZ | ▲ Buy | Grant | 869,110 | — | 1/23/2024 | View on chart |
| CORZ | ▲ Buy | Grant | 35,233 | — | 1/23/2024 | View on chart |
| CORZ | ▲ Buy | Grant | 869,110 | — | 1/23/2024 | View on chart |
| CORZ | ▲ Buy | Grant | 35,233 | — | 1/23/2024 | View on chart |
| CORZ | ▲ Buy | Grant | 3,835,368 | — | 1/23/2024 | View on chart |
| CORZ | ▲ Buy | Grant | 248,656 | — | 1/23/2024 | View on chart |
| CORZ | ▲ Buy | Grant | 10,629,668 | — | 1/23/2024 | View on chart |
| CORZ | ▲ Buy | Grant | 430,873 | — | 1/23/2024 | View on chart |
| CORZ | ▲ Buy | Grant | 800,210 | — | 1/23/2024 | View on chart |
| CORZ | ▲ Buy | Grant | 3,199,414 | — | 1/23/2024 | View on chart |
| CORZ | ▲ Buy | Grant | 129,704 | — | 1/23/2024 | View on chart |
| CORZ | ▲ Buy | Grant | 2,800,000 | $0 | 8/15/2022 | View on chart |
| CORZ | ▼ Sell | Tax Withholding | 1,238,126 | $2.1M | 7/5/2022 | View on chart |
| CORZ | ▲ Buy | Grant | 13,441,284 | $0 | 6/13/2022 | View on chart |
| CORZ | ▲ Buy | Grant | 4,880,466 | $0 | 6/13/2022 | View on chart |
| KBDC | ▼ Sell | Open Market | 91,810 | $1.4M | 10/1/2021 | View on chart |
| KBDC | ▼ Sell | Open Market | 36,724 | $551K | 6/1/2021 | View on chart |
| KBDC | ▼ Sell | Open Market | 36,724 | $551K | 6/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
HLF Featured in Mixed Stock Lists Amid High RSI
Recent articles from Yahoo and Benzinga discuss Herbalife in the context of long-term holdings and risk-off strategies, with one piece specifically citing reasons to avoid the stock. These mixed opinions appear while the stock trades near its 52-week high, reflecting a divergence between current price action and some analyst views. The news highlights ongoing debate over the company's value proposition among investors.
HLF Featured in Mixed Stock Lists Amid High RSI. Recent articles from Yahoo and Benzinga discuss Herbalife in the context of long-term holdings and risk-off strategies, with one piece specifically citing reasons to avoid the stock. These mixed opinions appear while the stock trades near its 52-week high, reflecting a divergence between current price action and some analyst views. The news highlights ongoing debate over the company's value proposition among investors.